Kidney Week

Abstract: TH-PO233

Correlation Between Albuminuria and Echocardiographic (Echo) Abnormalities in Individuals With Type 2 Diabetes (T2D): Insights From the Take Care of Me (TCoM) Program

Session Information

• Diabetic Kidney Disease: Clinical - I
  November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
  Abstract Time: 10:00 AM - 12:00 PM

Category: Diabetic Kidney Disease

• 602 Diabetic Kidney Disease: Clinical

Authors

• Vasnawala, Hardik, AstraZeneca, India, Bangalore, India

Hardik Vasnawala,

• Goncalves, Susana, AstraZeneca, Argentina, Buenos Aires, Argentina

Susana Goncalves,

• Khunti, Kamlesh, University of Leicester, Leicester, United Kingdom

Kamlesh Khunti,

• Fenici, Peter, AstraZeneca, S.p.A, Milan, Italy

Peter Fenici,

• L Heerspink, Hiddo Jan, Department of Clinical Pharmacology of the University Medical Center Groningen, Groningen, Netherlands

Hiddo Jan L Heerspink,

• Joshi, Shashank R., Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India

Shashank R. Joshi,

• Kosiborod, Mikhail, Saint Luke’s MidAmerica Heart Institute, University of Missouri-Kansas City, Kansas city, Missouri, United States

Mikhail Kosiborod,

• Lam, Carolyn, National Heart Center, Singapore, Singapore

Carolyn Lam,

• Nicolucci, Antonio, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy

Antonio Nicolucci,

• Ramirez, Larisa, AstraZeneca, Latam, San Jose, Costa Rica

Larisa Ramirez,

• Silva, Alejandra, AstraZeneca, Latam, San Jose, Costa Rica

Alejandra Silva,

• Surmont, Filip, AstraZeneca, China, Shanghai, China

Filip Surmont,

• Vazquez Mendez, Estefania, AstraZeneca, Mexico, Guadalajara, Mexico

Estefania Vazquez Mendez,

Background

Cardiovascular (CV) and renal diseases are the most common and morbid complications of T2D. The TCoM program, a subset of the iCaReMe global, cloud-based registry (NCT03549754), assessed the correlation between albuminuria and echo abnormalities in individuals with T2D.

Methods

Cross-sectional data of adults (>18 years) with T2D and no known cardiorenal complications (CRCs) at index visit, enrolled from routine clinical practice from Mexico, Argentina, Egypt, India, Malaysia, and the Philippines, were collected between December 2020 and December 2021. Correlation was assessed using Cramer’s V-value and Fisher’s exact/chi-square test.

Results

Of 12320 enrolled individuals (mean±SD age, 54.6±11.3 yrs; 59.3% women), 4853 had high/very high CV risk. Of these, 1506 (31%) had echo data; 450 (29.9%) of them had abnormal echo: 17.3% left ventricular hypertrophy, 16.8% left atrial enlargement, 4.3% diastolic dysfunction, 4.1% pulmonary hypertension, and 3.8% valvular disease. Echo abnormalities were significantly higher in individuals with albuminuria A2/A3 than those with A1 (33.5% vs 24.7%, p<0.05, v=0.094; Table). Significant correlation (p<0.05) was found between albuminuria and T2D duration (v=0.117), HbA1c (v=0.168), and CV risk (v=0.857).

Conclusion

Among individuals with T2D and high/very high CV risk from low-middle income countries, there is a significant correlation between albuminuria (stages A2/A3) and abnormal echo. Early detection of albuminuria through screening may be the key to effective management of CRCs in these individuals.

Factors associated with echocardiographic abnormalities and albuminuria

Funding

• Commercial Support –